文献速递湿疹皮炎与荨麻疹

奥马珠单抗治疗青少年及成人慢性特发性(自发性)荨麻疹的获益与危害:真实世界证据的Meta分析

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该Meta分析纳入截至2018年1月的观察性研究,评估奥马珠单抗治疗慢性特发性荨麻疹的真实世界获益与危害。结果显示UAS7评分平均降低25.6分,完全缓解率72.2%,不良事件率4.0%。作者认为真实世界获益与安全性达到或超过临床试验结果。

要点

  • 奥马珠单抗治疗与UAS7评分平均降低25.6分相关(95%CI -28.2至-23.0)。
  • 平均完全缓解率为72.2%,部分缓解率为17.8%。
  • 平均不良事件率为4.0%(任何严重程度)。

核心结论

  • 奥马珠单抗在慢性特发性荨麻疹真实世界治疗中的获益与安全性达到或超过临床试验结果。
  • 这些真实世界数据可能有助于指导临床治疗预期和政策决策。

研究设计与样本

  • 研究为Meta分析,检索PubMed、Embase、Web of Science和Cochrane数据库2006年1月1日至2018年1月1日发表的观察性研究及科学摘要。
  • 共纳入67篇文章(占筛选文章的35.2%),遵循PRISMA和MOOSE指南,由2名观察者独立选择和提取数据,采用随机效应Meta分析。

主要发现

  • 奥马珠单抗治疗与UAS7评分改善相关:平均降低25.6分(95%CI -28.2至-23.0;P < .001;15项研究,294例患者)。
  • 奥马珠单抗治疗与UAS评分改善相关:平均降低4.7分(95%CI -5.0至-4.4;P < .001;10项研究,1158例患者)。
  • 平均完全缓解率为72.2%(95%CI 66.1%-78.3%;P < .001;45项研究,1158例患者)。
  • 平均部分缓解率为17.8%(95%CI 11.7%-23.9%;P < .001;37项研究,908例患者)。
  • 平均不良事件率为4.0%(95%CI 1.0%-7.0%;P < .001;任何严重程度;47项研究,1314例患者)。

关键数值与推荐

  • UAS7评分范围0-42分,评分越高结局越差。
  • UAS评分范围0-6分,评分越高结局越差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) (also known as chronic spontaneous urticaria) in adolescents and adults with persistent hives not controlled with antihistamines. The effectiveness of omalizumab in the real-world management of CIU is largely unknown. OBJECTIVE: To quantitatively synthesize what is known about the benefits and harms of omalizumab in the real-world clinical management of CIU regarding urticaria activity, treatment response, and adverse events. DATA SOURCES: Published observational studies (January 1, 2006, to January 1, 2018) and scientific abstracts on the effectiveness of omalizumab in CIU were identified using PubMed, Embase, Web of Science, and Cochrane search engines; references were searched to identify additional studies. STUDY SELECTION: Included studies were observational in design and included at least 1 outcome in common with other studies and at a concurrent time point of exposure to omalizumab. A total of 67 articles (35.2% of those screened) were included in the analysis. DATA EXTRACTION AND SYNTHESIS: PRISMA and MOOSE guidelines were followed; independent selection and data extraction were completed by 2 observers. Random-effects meta-analyses were performed. MAIN OUTCOMES AND MEASURES: Main outcomes were change in weekly Urticaria Activity Score (UAS7; range, 0-42), change in Urticaria Activity Score (UAS; range 0-6) (higher score indicating worse outcome in both scales), complete and partial response rates (percentages), and adverse event rate (percentage). RESULTS: Omalizumab therapy was associated with an improvement in UAS7 scores (-25.6 points, 95% CI, -28.2 to -23.0; P < .001; 15 studies, 294 patients), an improvement in UAS scores (-4.7 points, 95% CI, -5.0 to -4.4, P < .001; 10 studies, 1158 patients), an average complete response rate of 72.2% (95% CI, 66.1%-78.3%; P < .001; 45 studies, 1158 patients) with an additional average partial response rate of 17.8% (95% CI, 11.7%-23.9%; P < .001; 37 studies, 908 patients), and an average adverse event rate of 4.0% (95% CI, 1.0%-7.0%; P < .001; any level of severity, 47 studies, 1314 patients). CONCLUSIONS AND RELEVANCE: Benefits and safety of omalizumab in the real-world treatment of CIU meet or exceed results gleaned from clinical trials. These real-world data on omalizumab in CIU may help inform both clinical treatment expectations and policy decision making.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Tharp MD, Bernstein JA, Kavati A, et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence. JAMA Dermatol. 2019. PMID: 30427977. doi:10.1001/jamadermatol.2018.3447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。